Tucaxen Tablets contain Tucatinib, a potent tyrosine kinase inhibitor specifically designed for the treatment of HER2-positive breast cancer. This targeted therapy works by selectively inhibiting the HER2 protein, interrupting the signaling pathways that stimulate cancer cell growth and proliferation. Tucaxen is primarily prescribed for patients with advanced or metastatic HER2-positive breast cancer who have previously undergone other treatments. The medication offers a precise mechanism of action to slow disease progression while minimizing damage to normal cells. Available in tablet form, Tucaxen requires strict adherence to prescribed dosages and regular monitoring for potential side effects such as diarrhea, liver dysfunction, and fatigue. Manufactured under rigorous quality controls, Tucaxen ensures pharmaceutical-grade purity and consistency, making it a trusted option in oncological care for HER2-positive breast cancer patients seeking targeted therapeutic intervention.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Tucatinib |
| Therapeutic Use | Treatment of HER2-positive advanced or metastatic breast cancer |
| Mechanism of Action | Selective tyrosine kinase inhibitor targeting HER2 protein |
| Dosage Form | Oral tablets |
| Patient Indication | Patients with prior cancer treatments for HER2-positive breast cancer |
| Manufacturing Standards | Produced under stringent pharmaceutical quality controls |
| Side Effect Monitoring | Requires clinical monitoring for liver function, diarrhea, and other side effects |
| Packaging | Contains specific dosage regimen as per oncologist prescription |
| Attributes | Description |
|---|---|
| Drug Class | Tyrosine Kinase Inhibitor |
| Target Protein | HER2 protein |
| Route of Administration | Oral |
| Packaging Type | Blister pack or strip of tablets |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Shelf Life | Typically 24 months from manufacturing date |
| Recommended Dosage | As prescribed by oncologist, commonly 300 mg twice daily |
| Common Side Effects | Diarrhea, fatigue, nausea, liver enzyme elevation |
| Manufacturer | Produced under strict GMP guidelines |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Tucaxen Tablets contain Tucatinib, which selectively inhibits the tyrosine kinase activity of the HER2 protein, preventing cancer cell growth and proliferation.
Tucaxen is prescribed for patients with advanced or metastatic HER2-positive breast cancer who have received prior cancer treatments.
Yes, patients should be monitored for side effects such as diarrhea, liver enzyme elevations, fatigue, and nausea during treatment.
Tucaxen is administered orally as tablets, with the dosage and schedule prescribed by an oncologist.
Tucaxen is manufactured under stringent Good Manufacturing Practices (GMP) to ensure safety, efficacy, and consistent pharmaceutical quality.
No, Tucaxen is typically prescribed for patients who have previously undergone other treatments; it is mainly indicated for advanced or metastatic cases.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
